Table 4 MRCI prevalence in the studied population according to the variables: gender, age, polypharmacy, potential drug interactions, potentially inappropriate medications for patients and therapeutic duplicity
Variable | Prevalence (%) | PR(a) | CI 95% | p-value |
|---|---|---|---|---|
Gender | ||||
Man | 47.62 | 1.00 | ||
Woman | 43.37 | 0.91 | (0.91–0.39) | 0.39 |
Age | ||||
≥ 80 | 56.14 | 0.87 | (0.65–1.16) | 0.21 |
< 80 | 64.71 | 1.00 | ||
Polypharmacy | ||||
Yes | 100 | 5.93 | (3.68–9.56) | <0.0001 |
No | 16.87 | 1.00 | ||
Potential drug interactions | ||||
Yes | 92.86 | 2.46 | (1.8–3.37) | <0.0001 |
No | 37.68 | 1.00 | ||
Potentially inappropriate medications for the elderly | ||||
Yes | 92.86 | 1.49 | (1.22–1.82) | <0.0001 |
No | 62.32 | 1.00 | ||
Therapeutic duplicity | ||||
Yes | 50 | 6.90 | (2.85–16.70) | <0.0001 |
No | 07.25 | 1.00 | ||